Paliperidona Teva (Paliperidone Palmitate)

Paliperidone palmitate, the active ingredient in Paliperidona Teva, is an antipsychotic presented as a sterile long‑acting intramuscular injection for intramuscular use. The formulation delivers a sustained release of paliperidone, allowing monthly or quarterly dosing to maintain therapeutic plasma levels. It is indicated for the management of schizophrenia and related psychotic disorders in adult patients.

GNH USA supplies Paliperidona Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. All batches are manufactured under EU Good Manufacturing Practice standards and undergo rigorous quality testing before release.

Paliperidone palmitate is used in the antipsychotic class to provide long‑acting maintenance therapy for psychotic conditions.

- Schizophrenia: Reduces positive and negative symptoms and helps prevent relapse in adult patients. - Schizoaffective disorder: Stabilizes mood and psychotic features, supporting long‑term disease control. - Maintenance therapy after oral stabilization: Provides sustained drug exposure, allowing less frequent dosing compared with daily oral paliperidone.

Paliperidona Teva may be associated with a range of adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Weight gain: increase in body weight over time. - Akathisia: feeling of inner restlessness. - Somnolence: drowsiness or sleepiness.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Tardive dyskinesia: persistent involuntary movements. - Severe orthostatic hypotension: marked drop in blood pressure upon standing. - Seizures: occurrence of convulsive episodes.

When prescribing Paliperidona Teva, clinicians should observe several safety measures.

- Monitor metabolic parameters: Check weight, glucose and lipid levels regularly. - Assess cardiovascular status: Observe blood pressure and heart rate for orthostatic changes. - Evaluate for movement disorders: Watch for signs of extrapyramidal symptoms or tardive dyskinesia. - Review pregnancy and lactation status: Use only if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Paliperidona Teva can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase paliperidone exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce paliperidone levels. - QT‑prolonging agents (e.g., haloperidol, quinidine): raise risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: additive hypotensive effect. - Antidiabetic medications: possible alteration of glucose control. - CNS depressants (benzodiazepines, opioids): enhanced sedation.